Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myomo, Inc. (NYSE American: MYO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Myomo is a wearable medical robotics company that develops and markets MyoPro myoelectric orthoses for individuals with neuromuscular disorders and upper-limb paralysis, and its filings offer detailed insight into how this business is structured and financed.
Through documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, Myomo reports information on revenue from MyoPro devices, gross margin, operating expenses, cash position and risk factors related to reimbursement, financing, product development and regulatory approvals. These filings also describe the company’s focus on its MyoPro product line, its relationships with orthotics and prosthetics providers and the Veterans Health Administration, and its dependence on third-party payers such as Medicare Part B and private insurers.
Current reports on Form 8-K document specific material events. For example, Myomo has filed 8-Ks describing a Loan and Security Agreement that provides term loans secured by a lien on the company’s assets, including intellectual property, together with associated warrants to purchase common stock and potential conversion rights. Another 8-K outlines a salary-for-restricted stock units program for certain executives. These filings explain key terms such as interest-only periods, maturity dates, financial covenants and equity-related features.
On Stock Titan, users can view these filings as they are made available from EDGAR and use AI-powered summaries to understand complex sections, including capital structure provisions, debt covenants, warrant terms and equity compensation arrangements. The page also surfaces Form 4 and other ownership-related filings, helping users monitor insider transactions and changes in beneficial ownership alongside the company’s broader financial and operational disclosures.
Myomo, Inc. (MYO) – Form 4 insider transaction
Chief Medical Officer Harry Kovelman reported the automatic sale of 13,054 common shares on 30 June 2025 at $2.19 per share. The transaction is coded “F,” indicating the shares were withheld solely to cover income taxes arising from the vesting of restricted stock units on 28 June 2025. After the sale, Kovelman still beneficially owns 140,618 shares, held directly. No derivative securities were acquired or disposed of, and no additional transactions are disclosed.
The filing appears to be a routine tax-related share withholding rather than a discretionary market sale and does not materially change insider ownership levels.
Myomo, Inc. (MYO) – Form 4 filing: Chief Financial Officer David A. Henry reported a Code “F” transaction on 30 June 2025, in which 23,587 shares of common stock were withheld and sold at $2.19 per share solely to satisfy income-tax obligations arising from the vesting of restricted stock units (RSUs) on 28 June 2025. After the automatic sale, the executive continues to hold 427,900 shares in direct ownership. No derivative security activity was reported, and the filing discloses no additional purchases or open-market sales. Such tax-withholding dispositions are routine and generally neutral with respect to the executive’s long-term ownership position and the company’s fundamentals.
Myomo, Inc. (MYO) – Form 144 filing: The notice discloses a proposed sale of 23,587 common shares by David Henry through Morgan Stanley, targeted for 30 June 2025 on the NYSE American. The shares have an aggregate market value of $51,655.53, equating to roughly 0.07 % of the company’s 35,978,922 shares outstanding, indicating an immaterial proportion of total equity.
The securities derive from the vesting of restricted stock units (RSUs) on 28 June 2025, when 65,000 shares were acquired from Myomo. In addition, the filer sold 8,373 shares on 06 June 2025 for gross proceeds of $24,867.81. No other financial data or operational commentary is provided in the filing.
Because the planned sale represents a very small percentage of outstanding shares and does not involve new share issuance, dilution is not a concern. Nonetheless, investors often monitor insider transactions for sentiment signals; repeated insider selling can be interpreted cautiously, even when associated with equity compensation events such as RSU vesting.